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Abstract
Receptor tyrosine kinases, such as VEGFR, PDGFR and EGFR, play important roles in
renal cancer. In this study, we investigated EGFR knockout as a therapeutic approach in
renal cell carcinoma (RCC). We showed that a renal cell carcinoma cell line (RC21) has
higher expression of EGFR as compared to other frequently used cell lines such as
HEK293, A549, Hela and DLD1. Ablation of EGFR by CRISPR/Cas9 significantly restrained
tumor cell growth and activated the MAPK (pERK1/2) pathway. The VEGFR and PDGFR
inhibitor, sunitinib, attenuated the expression of MAPK (pERK1/2) and pAKT induced by
EGFR loss and further inhibited EGFR-/- cell proliferation. We showed that loss of EGFR
eventually leads to resistance to SAHA and cisplatin. Furthermore, EGFR loss induced G2/
M phase arrest and resulted in an increased resistance to TNF-related apoptosis-inducing
ligand (TRAIL) in renal cell carcinoma. Thus, ablation of overexpressed EGFR by CRISPR/
Cas9 alone or in combination with sunitinib may be a new treatment option for renal cell
carcinoma.
Introduction
RCC is one of the most aggressive malignant tumors, accounting for 3% of adult malignancies
in Europe and the United States [1]. The 5-year survival rate of metastatic RCC is less than
10% [2]. Treatment options for RCC are limited due to multi-drug resistance including che-
motherapy and radiation resistance [3]. Given that RCC is a highly aggressive with poor prog-
nosis cancer, more intensive studies on tumorigenesis and new treatment strategies are
required.
The epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor
(VEGFR) and platelet-derived growth factor receptor (PDGFR) play significant roles in RCC
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progression. Multi-targeted (receptor) tyrosine kinase inhibitors such as sunitinib and sorafe-
nib are commonly used to treat patients with RCC. These TKIs act via blocking VEGFR and/
or PDGFR-β in tumor cells. However, more than 30% of patients with RCC who are treated
with sunitinib or sorafenib develop hypertension, of whom approximately 12% with a grade 3
hypertension [4]. Combination therapy is another treatment option in which patients are
administered with a mixture of different tyrosine kinase inhibitors (TKIs) to get a higher
response rate. Several phase III clinical trials (NCT02231749, NCT02420821 and
NCT01582672) are currently in process on such therapies. However, a phase II clinical trial
reported that sunitinib in combination with gefitinib (an EGFR-TKI) had comparable efficacy
to sunitinib as monotherapy [5].
Although crosstalk between EGFR, PDGFR and VEGFR is complicated, two key down-
stream pathways are shared between them; i.e. the PI3K/AKT and RAS/RAF/MEK/ERK onco-
genic pathways [6,7]. These two key pathways are common therapeutic targets for cancer
therapy. In this study, we investigated EGFR knockout as a therapeutic option in RCC using
CRISPR/Cas9 [8–10]. We also evaluated the inhibitory effects of multiple inhibitors as well as
alterations in PI3K/AKT and RAS/RAF/MEK/ERK downstream pathways in the EGFRwt/wt
and EGFR-/- renal cancer cells.
Materials and methods
Cell lines
HEK293 (human embryonic kidney), Hela (cervical cancer), A549 (non-small cell lung carci-
noma) and DLD1 (colorectal adenocarcinoma) cells were purchased from ATCC. HEK293
(human embryonic kidney) and Hela (cervical cancer), were cultured in DMEM containing
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. The renal carcinoma cell line
RC21 was described elsewhere [11]. RC21, A549 and DLD1 were cultured in RPMI-1640 with
10% FBS and 1% penicillin/streptomycin. Cells were cultured under a humidified 5% Carbon
dioxide (CO2) atmosphere at 37˚C.
Generating the RC21 EGFR knockout cell line using CRISPR/Cas9
Generating gene knockout cell line has been described previously [10]. Briefly, The guide
RNAs (gRNAs) were derived from the GeCKO (v2) library (Table 1). EGFR CRISPR/Cas9 KO
Plasmid (human) consists of a pool of three plasmids, each encoding the Cas9 nuclease and a
target-specific 20-nucleotide gRNA designed for maximum knockout efficiency. For transfec-
tion, 3 × 105 cells per well were seeded in a 6-well plate. CRISPR/Cas9 plasmids were co-trans-
fected with HDR plasmids which carried the puromycin resistance gene using Lipofectamine
3000 (Invitrogen, Carlsbad, USA). To pick up single clones, 1000 cells were seeded in a 10 cm
dish after transfection and puromycin selection for 72 hrs. After two weeks, the culture
medium was carefully removed and the dish was rinsed with PBS twice to remove floating
cells. Sterile cloning cylinders were placed over each colony. Then, 100 μL of 0.25% trypsin
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was added to each cylinder, followed by 5 min incubation at 37 ˚C. Next, 200 μL of medium
was added into each cylinder, mixed and the mixtures were transferred to a 6-well plate pre-
filled with 2 mL culture medium in each well. EGFR knockout clones further validated by
Sanger sequencing and western blot.
T7 endonuclease I assay to detect CRISPR/Cas9 induced mutations
Hek293 cells were harvested and genomic DNA was isolated using the (Qiagen, Germany) fol-
lowing manufacturer’s instructions. The concentration of the isolated genomic DNA was
determined using The NanoDrop One Spectrophotometer (ThermoFisher Scientific, USA).
Then a PCR was performed using Taq polymerase (NEB, USA) with primers in Table 2 for
amplification (Sigma-Aldrich, Germany). The PCR amplification was as following an initial
denaturation 95 ˚C for 5 mins, samples were subjected to 35 cycles of 30 denaturation at 95 ˚C,
annealing at 53 ˚C for 30 seconds followed by extension at 72 ˚C for 40 seconds. Amplified
DNA products were mixed with 1,5μl NEBuffer 2 and 3,0μl nuclease free water. An initial
denaturation was performed following a ramp rate -2 ˚C /second from 95 ˚C and then -0.1 ˚C/
second from 85 ˚C to 25 ˚C, subsequently, 1μl T7e1 enzyme (NEB, USA) was added and incu-
bated at 37 ˚C in a water bath for 15 mins. Gel electrophoresis was performed for detecting of
DNA fragments.
Antibodies and chemical reagents
The primary antibodies MAPK (Erk) (#9102, 1:1000), Akt (1:1000, #9272), Phospho-EGF
Receptor (Tyr1068) (1:1000, #2234), p(Thr308)-Akt (1:1000, #9275), Phospho-Akt (Ser473)
(1:1000, #9271), Phospho-MAPK (pERK) (1:1000, #9101), β-Actin (1:10000, #4967) were pur-
chased from Cell Signaling (Leiden, The Netherlands) and anti-EGFR (1:1000, sc-03-G) was
purchased from Santa Cruz Biotechnology(Texas, USA). Cetuximab (ERBITUX) was ordered
from Merck (Dietikon, Switzerland). Gefitinib (Iressa) was bought from Sigma (Zwijndrecht,
The Netherlands); sunitinib was purchased from LC Laboratories (Woburn, USA). Entinostat
and SAHA were purchased from Selleckchem (Munich, Germany). Staurosporine and cis-
platin were purchased from Sigma-Aldrich (Zwijndrecht, Nederland). Doxorubicin was pur-
chased from Teva Pharmaceuticals. All drugs were aliquoted in DMSO and stored at -20˚C.
The human epidermal growth factor (hEGF) and platelet-derived growth factor (PDGF) were
purchased from Sigma-Aldrich (Zwijndrecht, Nederland).
Immunoblotting
Cells were lysed using ELB-softer buffer (50mM Hepes pH7.5, 150mM NaCl, 5mM EDTA,
0,1% NP-40) with PhosSTOP Phosphatase Inhibitor Cocktail (Roche, Mannheim, Germany)
and a protease Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, USA). Protein concen-
tration was determined by a standard protocol according to the Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific, USA). Twenty micrograms of each sample was loaded and sepa-
rated by pre-cast SDS-PAGE (Bio-Rad, Hercules, USA) and transferred into a PVDF (polyvi-
nylidene difluoride) membrane. The membrane was incubated with blocking buffer
Table 2. List of PCR primers for detecting gene knockout/knock-in.
Name Strand Sequence
KO exon 2 F 5’- TGGACCTTGAGGGATTGTTT-3’
R 5’- CCAGATTAGCCTGTTTCTATTTGAT-3’
https://doi.org/10.1371/journal.pone.0232985.t002
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containing 5% skimmed milk with 0.1% (v/v) Tween 20 in 1x PBS (PBST) at room tempera-
ture (RT) for 1 hr. Then, the membrane was incubated overnight with the primary antibody at
4˚C, followed by the secondary antibody treatment at RT for 1 hr. Bands were imaged using
Western Lightning Plus-ECL kit (PerkinElmer, Waltham, USA) and were analyzed by GeneS-
nap image software (SynGene, Frederick, USA).
Flow cytometric analysis of EGFR membrane expression
Cells were washed twice with PBS and harvested by trypsin for 5 mins, followed by 1 hr incu-
bation with primary antibody or IgG isotype control on ice. Then, cells were washed by FACS
buffer (2% calf serum in PBS) three times and incubated with secondary antibody for 1 hr.
Next, cells were washed with FACS buffer three times and protein expression was determined
by FACSCalibur flow cytometer (BD, Franklin Lakes, USA).
Growth inhibition assay
A total of 3x103 cells per well were seeded in 96-well plates and cultured overnight. Afterwards,
cells were separately treated with different drugs for 3 days. Next, cells were incubated with
medium containing MTS reagent for 90 mins at 37˚C according to the instruction from Cell-
Titer 96 AQueous One Solution (Promega, Madison, USA). The absorbance was determined
using a Synergy H1 plate reader (BioTek, Winooski, USA) at wavelength of 490 nm. Experi-
ments were performed in triplicates and repeated for three times.
Clonogenic assay
Clonogenic assay has been described elsewhere [12]. Briefly, A total number of 20,000 cells per
well were seeded in a 12-well plate and cultured for 6. Then, the medium was gently removed.
Cells were washed with PBS, and then cells were fixed by using 4% formaldehyde. Cells were
stained with 1% crystal violet for 20 mins and washed thoroughly by PBS before colonies were
counted. For quantification, 0.5 ml 10% acetic acid per well was used to extract the dye. The
absorbance was detected at wavelength of 590 nm using a Synergy H1 plate reader (BioTek,
Winooski, USA). Experiments were performed in triplicate and repeated at least three times.
TRAIL protein production
The production and purification of TRAIL protein have been described previously [13].
Briefly, recombinant human sTRAIL protein was produced by E. coli BL21(DE3) in 2YT
medium with 100μg/mL ampicillin and 1% (w/v) glycerol at 37˚C to mid-log phase. The pro-
tein production was induced by IPTG (0.1mM) and ZnSO4 was added to help stabilize the tri-
mer formation. The cells were grown at 20˚C overnight after induction. The concentrated
pellet was disrupted by sonication. The purification was performed through cation exchange
chromatography and gel filtration.
Apoptosis assay and cell cycle analysis
A total of 5x105 cells per well were seeded in 6-well plates and cultured overnight. The cells
were treated with drugs for 24 hrs. Apoptosis and cell cycle were investigated using the
eBioscience™ Annexin V Apoptosis Detection Kit APC according to the manufacturer’s proto-
col (Thermo Fisher Scientific, Waltham, USA) by FACS Calibur flow cytometer (BD, Franklin
Lakes, USA). The FACS data were analyzed using FLOWJO v10.1.
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Results
EGFR is highly expressed in renal cell carcinoma
RC21 is a renal cell carcinoma cell line with overexpressed EGFR [11]. We used flow cytometry
to compare the EGFR expression levels in RC21 and four other commonly used cell lines
(HEK293, Hela, A549 and DLD1). We showed that the expression level of EGFR in RC21 is
13-fold higher than HEK293, 7-fold higher than DLD1, 5-fold higher than Hela and 4-fold
higher than A549 cells (S1 Fig).
Generating EGFR gene knockout cell lines using CRISPR/Cas9
To generate a RC21 EGFR knockout cell line, a CRISPR/Cas9 approach was employed using
two gRNAs targeting exon 2 of EGFR with the homology-directed DNA repair (HDR) tem-
plates specific to the cut sites of EGFR (Fig 1A). The knockout efficiency was pre-assessed in
HEK293 cell line using T7 Endonuclease 1 (T7E1) assay. The indel frequencies induced by
CRISPR/Cas9 were up to 60% after sorting for eGFP-positive cells by flow cytometry (S2 Fig).
The gRNA/Cas9 and HDR donor plasmids pool were co-transfected to RC21 cells. Four
Fig 1. (A) CRISPR-mediated EGFR knockout and homology directed repair (HDR). (B) Agarose gel electrophoresis of PCR-based genotyping
for identification of EGFR knockout clones. (C) Western blot analysis of RC21 EGFRwt/wt and EGFR-/- cells. (D) Flow cytometric analysis
shows EGFR expression in RC21 EGFRwt/wt and EGFR-/- cells.
https://doi.org/10.1371/journal.pone.0232985.g001
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independent EGFR knockout clones were picked and expanded and PCR results showed suc-
cessful disruption of EGFR exon 2 by insertion of a donor DNA fragment which was further
confirmed by Sanger sequencing (Fig 1A and 1B). Ablation of EGFR was also validated by
Western blot and flow cytometry (Fig 1C and 1D).
EGFR loss inhibits cell proliferation, but leads to resistance to cisplatin and
SAHA in renal cell carcinoma
To characterize the effect of EGFR loss on cancer cell growth, a clonogenic assay was per-
formed. RC21 EGFR-/- cells showed a significant reduction in cell proliferation and colony for-
mation property (Fig 2). Then, we tested several targeted and chemotherapeutic drugs on
RC21 EGFRwt/wt and EGFR-/- cells. Interestingly, RC21 EGFR-/- cells showed resistance to cis-
platin and SAHA in a dose dependent manner. We did not observe significant differences
between RC21 EGFRwt/wt and EGFR-/- cells upon treatment with TKIs and cetuximab (Fig 3).
EGFR loss leads to ERK activation
To investigate the impact of EGFR loss on the key downstream signaling pathways, we assessed
alterations in the expression of MAPK/ERK and PI3K/Akt in RC21 EGFRwt/wt and EGFR-/-
cells. We specifically evaluated expression of EGFR, pEGFR, Akt, pAkt, ERK and MAPK
(pERK) by Western blot. As expected, we did not detect EGFR or pEGFR in EGFR-/- cells (Fig
4A and 4D). However, we observed a relatively higher level of pERK1/2 in RC21 EGFR-/- cells
as compared to EGFRwt/wt cells with or without stimulation with EGF or PDGF (Fig 4A and
4B). We also found a lower level of pAKT in RC21 EGFR-/- cells than the parental cells upon
stimulation with PDGF (Fig 4B).
Sunitinib attenuates pERK1/2 and pAKT levels and further inhibits RC21
EGFR-/- cell proliferation
Sunitinib is a receptor TKI that can inhibit cellular signaling induced by VEGFR and PDGFR.
To determine the effect of sunitinib on cell proliferation and downstream pathway, we treated
RC21 EGFRwt/wt and EGFR-/- cells with sunitinib at different doses. We observed that sunitinib
induces a marked suppression of proliferation in RC21 EGFR-/- cells as compared to RC21
Fig 2. Colony formation assay of RC21 EGFRwt/wt and EGFR-/- cells to determine cell proliferation ability of four
independent EGFR knockout clones.
https://doi.org/10.1371/journal.pone.0232985.g002
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EGFRwt/wt. Furthermore, we found that the highly expressed pERK1/2 and pAkt introduced by
EGFR loss can be abolished by sunitinib in EGFR-/- cells (Fig 4C and 4D).
EGFR loss reduces G0/G1 phase population and leads to resistance to
apoptosis
To determine the effect of EGFR loss on cell cycle and apoptosis, an APC-conjugated
Annexin-V/Propidium Iodide assay was performed. Loss of EGFR decreased G0/G1 phase
population as and induced G2/M phase arrest. Moreover, G0/G1 phase population in RC21
EGFR-/- cells was further decreased upon treatment with staurosporine (100 nM) (Fig 5A). For
apoptosis analysis, we used trimeric recombinant human TRAIL (rhTRAIL) to stimulate the
apoptotic pathway. Our data show that EGFR loss leads to resistance to apoptosis induced by
rhTRAIL (50ng/ml) in renal cancer cells (Fig 5B).
Discussion
EGFR plays an essential role in the tumorigenesis of a variety of cancers including RCC, where
it is commonly overexpressed. EGFR expression is considered as an important biomarker for
predicting response to TKIs. Nevertheless, so far, no satisfactory therapeutic results have been
achieved using EGFR-TKIs in clinical trials for RCC. In this study, we examined whether
EGFR knockout in combination with different small molecular inhibitors or a therapeutic pro-
tein (TRAIL) can be used as a treatment option for RCC. We showed that disruption of over-
expressed EGFR dramatically inhibits the proliferation of RCC and arrests cells at G2/M
checkpoint. Furthermore, we found that inhibition of PDGFR and VEGFR by sunitinib can
attenuate the expression of pERK1/2 and pAKT induced by EGFR loss. We did not observe
any difference in the viability of RC21 EGFRwt/wt and EGFR-/- cells after gefitinib treatment.
This can be explained by the significantly higher affinity of gefitinib to the EGFR mutant cells
than to the wild-type.
Fig 3. Treatment of the RC21 EGFRwt/wt and EGFR-/- cells with different anti-cancer drugs. Cells were treated with the indicated drugs at
indicated concentrations for 72 hrs and the cell viability was determined using MTS assay. For staurosporine, cell viability was measured after
24 hrs due to its toxicity. All data in the graphs are represented as mean ± SD (n�3), two-tailed unpaired student’s t-test: �p-values<0.05; ��p-
values<0.01; ���p-values<0.001.
https://doi.org/10.1371/journal.pone.0232985.g003
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Overexpression of EGFR is associated with poorer survival in many cancers [14,15]. We
showed that RC21 also has a much higher expression of EGFR as compared to a number of
commonly used cell lines, such as HEK293, DLD1, A549 and Hela cells. Of note, human
embryonic kidney cells (HEK293) have the lowest expression levels of EGFR among the tested
cell lines as compared to RC21, suggesting EGFR as a tumor biomarker or target in RCC.
Overexpression of EGFR is thought to play an important role in proliferation and survival of
tumor cells in a variety of cancers [16]. It is also considered as a response biomarker for
EGFR-TKIs or EGFR-antibodies, including gefitinib, elortinib, afatinib and cetuximab [17].
The underlying mechanisms of limited drug response and resistance to EGFR targeted ther-
apies in RCC are not fully understood which is mainly due to lack of means for complete elimi-
nation of EGFR from cells. It is generally considered that the RNAi and shRNA cannot
efficiently inhibit EGFR expression and the residual EGFR in cells may contribute to tumor
development [18]. Besides, homozygous EGFR knockout in mice results in an early embryonic
lethality [16]. In addition, EGFR inhibitors cannot completely inhibit EGFR signaling because
Fig 4. Downstream pathways and cell proliferation alterations with different treatments (A) Western blot analysis of RC21 EGFRwt/wt and EGFR-/- cells stimulated with
EGF at different dose and time points. (B) Western blot analysis of RC21 EGFRwt/wt and EGFR-/- cells stimulated with PDGF at different dose and time points. (C)
Clonogenic assay to test cell proliferation and western blot analysis of downstream pathway after treatment with sunitinib. (D) Western blot quantification. The graph was
generated through quantifying blots from three independent experiments by ImageJ and normalizing the intensity of the bands to the lane at 0 min.
https://doi.org/10.1371/journal.pone.0232985.g004
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of dose limitations toxicity and others. EGFR inhibitor (tyrosine kinase inhibitor) could block
the tyrosine kinase activity of EGFR, but it cannot fully block other function of EGFR. It has
been reported that EGFR has various functions other than tyrosine kinase activity, such as
many ligands depending functions, crosstalk with other proteins and others [19,20]. Thus, the
precise role of EGFR in tumor development is difficult to unravel. Here, we generated RC21
EGFR knockout cell line by HDR using CRISPR/Cas9. We show that EGFR loss inhibits renal
cancer cell proliferation. It indicates CRISPR-mediated disruption of EGFR may be a promis-
ing therapeutic option for RCC in the future [21]. Given the importance of EGFR overexpres-
sion for tumor survival, growth and drug resistance, future studies are needed to explore
whether overexpressed EGFR knockout can be an option for more cancers [22]. However, for
clinical use, optimization of the delivery methods for specifically targeting overexpressed
EGFR in cancer cells needs more in depth investigations [23]; for instance, optimization of
specific gene therapy delivery vehicles based on EGFR [24]
We showed a higher level of MAPK/pERK in RC21 EGFR-/- cells as compared to the
EGFRwt/wt cells indicative of a bypass mechanism for activation of MAPK/pERK pathway
upon loss of EGFR. We observed that the proliferation of RC21 EGFR-/- can be inhibited by
sunitinib. Furthermore, the overactivated MAPK/pERK and pAKT in RC21 EGFR-/- cells are
inhibited by sunitinib suggesting VEGFR and/or PDGFR may be implicated in this bypass
mechanism. However, a phase I/II trial did not show sunitinib plus gefitinib more efficacy to
sunitinib monotherapy [5]. One possibility might be that gefitinib only shows therapeutic
effects on patients with certain EGFR mutations, however, in this clinical trial, it was unknown
whether these RCC patients had EGFR mutations or not. In concordance with our data, several
studies have shown that reactivation of MAPK/ERK signaling pathway frequently occurs in
TKIs-based therapies [25–28]. One of the most common adverse events for treatment of RCC
is hypertension, which is closely correlated to the dose of VEGFR inhibitors (sunitinib, etc.)
Fig 5. Annexin-V/Propidium Iodide staining for cell cycle and apoptosis analysis of RC21 EGFRwt/wt and EGFR-/- cells. (A)
Propidium Iodide staining for cell cycle analysis in the presence and absence of Staurosporine. (B) Annexin-V/Propidium Iodide
staining for apoptosis analysis in the presence and absence of TRAIL.
https://doi.org/10.1371/journal.pone.0232985.g005
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[29]. Future studies are needed to further investigate the outcomes of hypertension upon the
combination of EGFR and/or VEGFR/PDGFR inhibition. Altogether, evaluation of certain
receptor tyrosine kinases before and after treatment could be beneficial for patients with RCC.
Furthermore, combination targeted therapy might be a more promising strategy to overcome
drug resistance in these patients.
Our results show that EGFR loss leads to the resistance of renal cancer cells to cisplatin,
HDAC inhibitors and TRAIL [30–32]. Several studies have shown that the EGFR status is asso-
ciated with drug resistance in cancer [33–35]. According to our observations, disruption of
overexpressed EGFR suppresses cancer cell growth, but ultimately leads to the reactivation of
pERK and/or pAKT via an EGFR independent mechanism and drug resistance. We previously
reported a promising anticancer activity of EGFR-Selective TRAIL Fusion Protein in RC21
[11]. However, in this study we show that loss of EGFR results in the resistance of cancer cells
to TRAIL. Future studies should include more RCC with different subtypes, and those results
observed in vitro should be further confirmed by in vivo studies before moving to clinic. Also,
it would be important to check the patients EGFR status (mutations or overexpression) before
treatment if EGFR inhibitors or antibodies are applied in clinic. Taken together, the response
of tumor cells to TRAIL might also be related to the expression level of EGFR.
In conclusion, knockout of overexpressed EGFR dramatically inhibits renal cancer cell
growth. Although EGFR loss leads to cell survival and multiple drug resistance, sunitinib can
further inhibit renal cancer cell proliferation upon loss of EGFR (Fig 6).
Supporting information
S1 Fig. Flow cytometric analysis of EGFR in RC21, Hela, A549 and DLD1 and HEK293
cells.
(TIF)
Fig 6. Proposed model of CRISPR/Cas9 mediated EGFR knockout in combination with sunitinib and its effect on
MAPK signaling pathway in renal cell carcinoma.
https://doi.org/10.1371/journal.pone.0232985.g006
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